The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Effect of wnt aberrant methylation and epidermal growth factor receptor pathway mutation on responsiveness of non-small cell lung cancer to gefitinib and erlotinib.
J. Zhu
No relevant relationships to disclose
J. Wang
No relevant relationships to disclose
H. Bai
No relevant relationships to disclose
J. Zhao
No relevant relationships to disclose
Z. Wang
No relevant relationships to disclose
M. Zhuo
No relevant relationships to disclose
T. An
No relevant relationships to disclose
J. Duan
No relevant relationships to disclose
L. Yang
No relevant relationships to disclose
M. Wu
No relevant relationships to disclose
Q. Guo
No relevant relationships to disclose
X. Liu
No relevant relationships to disclose
S. Wang
No relevant relationships to disclose
Y. Wang
No relevant relationships to disclose